Displaying drugs 10251 - 10275 of 12439 in total
Platelet Lysate
Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors. It is extracted through lysis of the plasma membrane of platelets. Because white cell antigens are low in prepared lysate, there is a minimized likelihood...
Investigational
Matched Description: … [A220188] It is extracted through lysis of the plasma membrane of platelets. ... Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular ... Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses …
BMS-919373
BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers).
Investigational
Matched Description: … BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on ... the Electrical Activity of the Heart Using Pacemakers). …
ATL1101
ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis. ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis.
Investigational
Matched Description: … ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis ... a protein involved in the regulation of cell overgrowth in psoriasis. ... ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, …
Ciraparantag
Ciraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban).
Investigational
Matched Description: … Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban). ... Ciraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single …
Etrolizumab
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration and retention of intestinal-homing lymphocytes.[A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some...
Investigational
Matched Description: … in undesirable blockade of lymphocyte CNS trafficking and reported cases of progressive multifocal leukoencephalopathy ... [A244574] In the case of [natalizumab], which targets the α4 integrin subunit, this has also resulted ... gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration and retention of …
Molybdenum cofactor
Absence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage usually leading to death within months of birth, due to the lack of active sulfite oxidase.
Experimental
Matched Description: … Absence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage ... usually leading to death within months of birth, due to the lack of active sulfite oxidase. …
NS-2359
NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action". This mode of action is expected to produce an optimal...
Investigational
Matched Description: … of an earlier onset of action compared to antidepressants already on the market. ... a desired "triple-mode-of-action". ... with a new, unique drug profile expected to yield important benefits compared to existing treatments of …
Plozalizumab
Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to...
Investigational
Matched Description: … of atherosclerosis. ... to sites of inflammation. ... Plozalizumab has been investigated for the treatment of Atherosclerosis. …
Paliroden
Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines. Studies show that use of paliroden increased the rate of formation of both neural progenitors and mature neurons. It is indicated for use in Alzheimer's Disease and Parkinson’s.
Investigational
Matched Description: … Studies show that use of paliroden increased the rate of formation of both neural progenitors and mature ... Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous …
GB-13
GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.
Investigational
Matched Description: … mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A. ... GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered …
CP-39,332
CP-39,332 is a serotonin-norepinephrine reuptake inhibitor (SNRI). It is part of a group of monoamine reuptake inhibitor stereoisomers including tametraline (1R,4S-), CP-24,442 (1S,4R-), CP-22,185 (cis-), and CP-22,186 that show varying efficiency. However, none of the members of this stereoisomers has been marketed.
Experimental
Matched Description: … However, none of the members of this stereoisomers has been marketed. ... It is part of a group of monoamine reuptake inhibitor stereoisomers including tametraline (1R,4S-), CP …
PI-103
PI-103 is an inhibitor of p110α of class I PI3K.
Investigational
Matched Description: … PI-103 is an inhibitor of p110α of class I PI3K.[A253092] …
Entolimod
Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer, Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among others.
Investigational
Matched Description: … , Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among ... Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer …
MUL001
MUL001 is live attenuated strain of Salmonella typhimurium being investigated for the treatment of schwannomas.
Investigational
Matched Description: … MUL001 is live attenuated strain of _Salmonella typhimurium_ being investigated for the treatment of …
Efavaleukin alfa
Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker. It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease).
Investigational
Matched Description: … G Fc domain by way of a G4S linker. ... Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin ... It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With …
APR-548
APR-548 is an analog of eprenetapopt and a reactivator of mutant p53.
Investigational
Matched Description: … APR-548 is an analog of [eprenetapopt] and a reactivator of mutant p53. …
Stannsoporfin
Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing jaundice.
Investigational
Matched Description: … WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing ... Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of …
Ferric pyrophosphate
Ferric pyrophosphate is an iron replacement product. Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma. The ferric ion is strongly complexed by pyrophosphate. It presents an increasing interest as this insoluble...
Experimental
Matched Description: … interactions of iron in plasma. ... side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of …
NTx-265
NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause of death worldwide. In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of...
Investigational
Matched Description: … of death worldwide. ... NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and ... In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. …
Tallimustine
Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA.[A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as brostallicin, which have a favourable cytotoxicity/myelotoxicity ratio.[A182039,A182045] Newer generations of DNA...
Experimental
Matched Description: … minor groove of DNA. ... Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the ... [A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour …
Elezanumab
Elezanumab is under investigation in clinical trial NCT03737812 (A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis).
Investigational
Matched Description: … Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis). ... Elezanumab is under investigation in clinical trial NCT03737812 (A Study to Assess the Safety and Efficacy of …
MK-0773
MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)).
Investigational
Matched Description: … MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK ... -0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)). …
Demcizumab
Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
Investigational
Matched Description: … Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung. …
5alpha-androstane-3beta,17alpha-diol
5alpha-androstane-3beta,17alpha-diol is the unspecified form of the steroid, normally a major metabolite of testosterone with androgenic activity. It has been implicated as a regulator of gonadotropin secretion.
Experimental
Matched Description: … of [testosterone] with androgenic activity. ... It has been implicated as a regulator of gonadotropin secretion. ... 5alpha-androstane-3beta,17alpha-diol is the unspecified form of the steroid, normally a major metabolite …
GSK-945237
GSK-945237 is under investigation in clinical trial NCT01039610 (A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237...
Investigational
Matched Description: … a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology ... Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.). ... Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of …
Displaying drugs 10251 - 10275 of 12439 in total